• linkedin
  • Increase Font
  • Sharebar

    Atopic dermatitis: Biologics to watch in 2018

     

     

    Targeting IL-22

    Initial studies of ILV-094, a novel antibody which targets IL-22, showed that this agent has favorable pharmacokinetics and toxicity. It’s now being evaluated as an intravenous treatment in a randomized, placebo-controlled phase 2 trial in adults with moderate-to-severe AD.

    “Because IL-22 is a potential key cytokine in AD, its inhibition may provide advantages over other available treatments through potentially increased safety and specific targeting compared with other immunosuppressants,” Patel and Strowd said in their review.

    Targeting IL-17

    IL-17 production plays a significant role in the pathogenesis of psoriasis, and is present in smaller amounts in AD lesions, according to the authors. As a result, some biologic medications evaluated in psoriasis patients are now being studied as treatments for AD.

    The IL-17 antibody secukinumab is being evaluated in one randomized, placebo-controlled phase 2 trial that is currently recruiting patients with moderate-to-severe AD.

    There are several case reports on patients with AD receiving ustekinumab, an anti-IL12/23 biologic medication that is effective in psoriasis. Some of the case reports say the AD patient responded well to ustekinumab treatment, while others reported only partial or no response, according to Patel and Strowd.

    In a 33-patient randomized, placebo-controlled phase 2 study, AD patients treated with ustekinumab had higher SCORAD50 scores vs placebo, investigators reported. However, results did not reach statistical significance, possibly due to background use of topical glucocorticosteroids or insufficient dosing, they said.

     

     

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow